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Low-dose rate brachytherapy has become a mainstream treatment option for men diagnosed with prostate cancer because of
excellent long-term treatment outcomes in low-, intermediate-, and high-risk patients. To a great extend due to patient lead
advocacyforminimallyinvasivetreatmentoptions,high-qualityprostateimplantshavebecomewidelyavailableintheUS,Europe,
and Japan. High-dose-rate (HDR) afterloading brachytherapy in the management of localised prostate cancer has practical,
physical, and biological advantages over low-dose-rate seed brachytherapy. There are no free live sources used, no risk of source
loss, and since the implant is a temporary procedure following discharge no issues with regard to radioprotection use of existing
facilities exist. Patients with localized prostate cancer may beneﬁt from high-dose-rate brachytherapy, which may be used alone in
certain circumstances or in combination with external-beam radiotherapy in other settings. The purpose of this paper is to present
theessentials of brachytherapies techniques along with the most important studies that support their eﬀectiveness inthetreatment
of prostate cancer.
Copyright © 2009 Georgios Koukourakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Localized prostate cancer can be cured by a variety of
treatment options with the standard approaches being
radiotherapy (RT) and radical prostatectomy. RT represents
an alternative to surgery since this approach may provide
excellent results in patients well selected for the procedure
[1, 2]. Nevertheless, in order to achieve optimal rates of
disease control, research has shown that a suﬃciently high
RT dose must be administered [3–5].
The two main modalities of administaring radiotherapy
are external X-ray beams generated by a linear accelerator
[4], known as external-beam radiotherapy and the implan-
tation of radioactive sources directly into the tumor, known
as interstitial brachytherapy. In contrary to external-beam
RT, in interstitial brachytherapy, the radiation does not pass
through superﬁcial tissues to reach an internal target. Far
from it, the radioactive source (i.e., seed) in interstitial
brachytherapy releases most of its dose close to its location.
External-beam RT and interstitial brachytherapy can be used
alone or in combination to take advantage of their unique
attributes.
Permanent implantation and temporary implantation
represent the two main categories of interstitial brachyther-
apy. In permanent implantation, the radioactive sources
remain in the tissues, whereas in temporary implantation,
the radioactive sources are removed after the desired radi-
ation dose is achieved. Brachytherapy can also be amply
depicted by the rate at which the dose is delivered, known as
the dose rate. The International Commission on Radiation
Units & Measurements refers to a dose rate of 40 to 200cGy
perhour(cGy/h)asalowdoserate(LDR),200to1200cGy/h
as a moderate dose rate, and greater than 1200cGy/h as a
high dose rate (HDR) [6].
Either permanent or temporary radioactive source
implantation can be used in brachytherapy for patients
with prostate cancer, with the dose given at either a very
LDR or an HDR. Permanent interstitial brachytherapy for
prostate cancer, commonly referred to as prostate seed
implantation, uses either iodine 125 (125I) or palladium
103 (103P d )a sr a d i o a c t i v es o u r c e sf o rc a s e si n v o l v i n g
very LDR (i.e., <40cGy/h). Contrary, HDR brachytherapy
for prostate cancer uses the temporary placement of a2 Advances in Urology
high-activity iridium 192 (192Ir) radioactive source, which
delivers a high radiation dose over a short period.
The purpose of this paper is to present an overview of the
useofbrachytherapyasacurativetreatmentforpatientswith
localized prostate cancer. The results of LDR brachytherapy
in patients with low-, intermediate-, and high-risk prostate
cancer along with HDR brachytherapy when used alone or
as a high-dose supplement combined with external-beam RT
for these patients are described. We also describe the method
of administration of LDR and HDR brachytherapy, the
potential advantages and disadvantages of HDR compared
with other forms of brachytherapy, and the directions that
this form of treatment may take in the future as its use is
further investigated.
2.MaterialsandMethods
2.1. Identiﬁcation of Eligible Studies. We searched MEDLINE
and the Cochrane Central Register of Controlled Trials
(last search on December 2008) using combinations of
terms, such as prostate cancer, brachytherapy, low-dose
rate, high-dose rate, and eﬃcacy. We considered all English
language controlled trials providing information about the
eﬀectiveness of low-dose or high-dose-rate brachytherapy
on cancer treatment of prostate, adverse proﬁle eﬀects, and
future directions of ongoing research as eligible.
2.2. Data Extraction. We extracted information from each
eligible study. The data recorded, included author’s name,
yearofpublication,numberofpatientsincludedinthestudy,
combination(s) of treatment used (brachytherapy alone or
in combination with external radiation therapy), percentage
overall response, median time to progression, and median
survival.
3. ImplantTechniques LDR
3.1. Real Time. The real-time method of brachytherapy
technique for prostate cancer was developed in 1990 by
physiciansattheMountSinaiMedicalCenter.Thistechnique
is heavily based on detailed clinical knowledge of the
transverse and sagittal ultrasound anatomy of the prostate
gland. According to the original inception of this method,
an activity per volume table (nomogram) is used to ﬁnd
the proper amount of activity for the seeds to be implanted.
Reliant on the concepts formulated by Patterson and Parker,
a peripherally weighted implant can be completed by
following a relatively accurate set of guidelines [4].
T h eﬁ r s ts t e pi sd e t e r m i n a t i o no fp r o s t a t ev o l u m eb y
applying an ellipsoid formula (height χ width χ length χ
0.52). This volume is used to determine the number of seeds
and total activity ordered for the patient by referring to a
look-up table. In the operating room, the prostate volume
is recalculated using step-section planimetry at 5-mm inter-
vals from base to apex. Three longitudinal measurements
(anterior, middle, and posterior) of the prostate are made
in the midline to ﬁnd the average length of the gland; this
i m p o r t a n ts t e ps e r v e sa sag e n e r a lg u i d ef o rt h en u m b e ro f
seeds to be placed within the periphery and interior of the
gland. The suggested seed activities for both I-125 (range
0.3–0.6mCi) and Pd-103 (1.5–3U) are titrated as such to
give a continuous isodose line with each other if placed no
further than 1cm apart. Therefore, a prostate length of 3cm
will require 4 seeds, 1 at both the apex and base and 2 in
the middle. A 4-cm length will require 5 seeds and so forth.
The number of peripheral needles is determined by taking
a circumferential measurement at the prostate’s greatest
transverse diameter. If the circumference is 12cm, then at
least 12 needles should be used. The ﬁnal decision on the
number of needles and spacing between needles and seeds
willbesomewhatdependentontheactivityperseedselected.
A higher activity will allow greater spacing (and therefore
fewer needles and seeds) but at a cost of needing to be
more conservative with proximity to the urethra and rectum.
These simple measurements, in addition to referencing the
look-up table, allow one to have a reliable road map for the
seed implant without the use of a computer-mediated plan.
Inaddition,itallowstheimplantteamtoworkfromthesame
setofreproducibleassumptionstoevaluatenewtechnologies
or software innovations [7, 8].
The implantation is purposively divided into an ini-
tial peripheral and subsequent interior phase. Placing the
peripheral needles only greatly improves the imaging of
the anterior needles and seeds. As this technique is highly
dependent on direct visualization of the position of each
needle and seed, any interference caused by the interior
needles could contribute to an inferior dosimetric outcome.
The goal of the interior needle and seed placement is to
deliver the dose to the base and apex of the gland, to provide
doseescalationifdesired,andtosupplementany“cold”areas
not covered adequately by peripheral seed placement.
The initial phase consists of peripheral needle placement
(usually 12–18 needles) just inside the prostate capsule, with
approximately 1-cm spacing, using the greatest transverse
image of the prostate. During this process, it is important,
although not imperative, that bilateral needle symmetry
is achieved within the prostate. Although the length of
the prostate gland and the number of needles required
are known, the precise number of seeds required may
need to be adjusted on the basis of the evaluation of the
intraoperative treatment plan, which is developed in tandem
with placement of the peripheral needles. When centers are
ﬁrst starting utilization of this technique, an even loading
of the peripheral needles from base to apex as identiﬁed
on the sagittal image, which depicts the entire length of
the Foley catheter, would be recommended. For centers
with experience, integration of the treatment planning
computer into the determination of precise needle and seed
placement can allow for extremely conformal implants that
simultaneously deliver an oncologically optimal dose to the
entire gland while avoiding hot spots near the urethra. From
a technical standpoint, it is important to also remember
that the posterior needles should be placed well beyond
the prostate capsule into the prostate parenchyma, at least
5mm from the capsule and/or 8mm from the inner rectal
mucosa.Thiswillassurethattherectaldoseiswellwithinthe
acceptable range. Generally, 75% of the seeds are placed inAdvances in Urology 3
the periphery, in accordance with the principles of Paterson
and Parker. If one uses an intraoperative treatment planning
software system, it is very common, especially in smaller
glands <35cm3 for 80%–85% of the seeds to be deposited
in the periphery of the gland. After insertion of peripheral
needles to take into account the eﬀect of edema, prostate
deformation, and precise needle position, the images are
again recaptured in the treatment planning system and the
initial plan is re-evaluated in light of the new position
of the prostate. This re-evaluation serves as an additional
opportunity to optimize the implant dosimetrically and
to critically evaluate peripheral needle distribution. The
radioactive sources are placed individually using the sagittal
setting of the probe. It is important for the brachytherapist
to identify prostatic anatomy before the placement of the
sources by referring often to the midline sagittal image to
ensure that probe movement and prostate movement are
properly accounted for as the sources are placed throughout
the peripheral needles. In addition, during this process the
exact seed position is mapped by the dosimetrist using the
real-time treatment planning software. If a seed slips or
clumps, this event is accounted for and its consequences
can be evaluated and adjusted for during the remainder of
the implant procedure [9]. For source placement, the Mick
applicator (Mick TP-200; Mick Radionuclear Instruments,
Mount Vernon, NY) is used. It is important to remember
that the prostate is a three-dimensional object in terms
of its relations to the bladder, urethra, and rectum. The
Mick applicator allows the operator the freedom to place
seeds closer together or farther apart from each other as
required by an individual’s anatomy. This is particularly
important for insertion of the peripheral apical seeds. Here
the prostate anatomy is best visualized by sagittal imaging,
and a mechanistic approach is best avoided to ensure that
seedsarenotplacedintotheperiprostatictissue,whichatthis
point consists largely of perirectal musculature. In addition,
the treatment planning system allows the brachytherapist to
judge in 3 dimensions where he or she is at in relation to
the urethra throughout the procedure. For order of needle
implantation, it is best to be consistent in approach to allow
the dosimetry team to follow the progress of the implant
accurately. Generally the needles furthest from the probe are
the most diﬃcult to visualize and should be implanted ﬁrst,
with progression toward the posterior needles near the probe
[10].
After the entire periphery is implanted, insertion of
interior needles is then undertaken, with the remaining
25% of total activity implanted. This is where the treatment
planning computer is particularly important because it
allows another opportunity to ensure the dosimetric quality
of the implant. In addition, one can often test new dose
distributionsbyvaryingneedlelocationtobestﬁttheunique
characteristics of the implant to this point. Usually 4–7
interiorneedlesareused,locatedatleast5mmawayfromthe
urethra. The purpose of the interior seeds is to adequately
cover the base and apex and not necessarily to provide a
high amount of radiation to the center. For centers that are
beginning an implant program, we advocate internal needle
placement in a U-shape around the urethra. As one gains
conﬁdence in the procedure and the use of intraoperative
treatment planning software, the inner needle distribution
can be more variable and continue to fulﬁll the planned
dose constraints. In addition, at this point the intraoperative
dosimetry system may be used to rationalize the use of
fewer seeds than originally suggested by the nomogram. It is
important to always place at least one seed at the apex and
at the base, regardless of what the intraoperative software
suggests to ensure adequate 30-day postimplant dosimetry
[11–14].
Patients with biopsy-conﬁrmed seminal vesicle involve-
ment and negative nodal involvement should have vesicles
implanted. Deposition of seeds is accomplished through the
peripheral needles or through 4-5 additional needles that are
placed in the seminal vesicles after removal of the interior
ones. The seeds are placed in the anterior and posterior walls
to ensure that the prescription dose cloud covers at least the
proximal half of the seminal vesicles [15, 16].
When all seeds are implanted, a dynamic cystogram
under ﬂuoroscopy is performed to exclude the possibility of
seeds placed in the bladder or in the urethra. If present, these
can be removed before the patient is taken to the recovery
room.
3.2. Preplan. After the introduction of image-guided seed
deposition with the use of axial transrectal ultrasound by
Holm, physicians at the Seattle Prostate Institute reﬁned this
original technique by developing the preplanned method of
prostate brachytherapy in the mid 1980s [17]. According
to this method, a plan is created by the physics staﬀ af e w
days before the implant by using the transverse transrectal
ultrasound images taken up in the oﬃce. The patient is
similarly positioned in the operating room to duplicate the
preplan, the predetermined coordinates are identiﬁed, and
preloaded needles are then placed.
The plan starts with a volume study of the prostate in the
examination oﬃce, where transverse images are generated at
5-mm intervals and carefully outlined with a light pen. Then
each of the images is entered into the treatment planning
computer software that generates a three-dimensional model
of the gland and calculates the position of each seed into
the prostate with dose designation. Finally, this plan is used
in the operating room where physicians attempt to put the
patient in the same position as whenthe preplan wascreated,
bymeticulousduplicationofexternalset-upparameterssuch
as hip and knee angles. Needles are preloaded with spacers
and are then inserted by the use of a template through the
perineum in the prostate. The transrectal ultrasound probe
is not used to direct the seed placement but is used to assist
in the recreation of the preplan and assure that the needles
are positioned in the predetermined locations [18, 19]. The
implant begins anteriorly and proceeds posteriorly. Each
needle is inserted into its preplanned grid location and
then is carefullywithdrawn, keeping the obturator stationary
for the entire row of alternated seeds to be placed in the
predeterminedposition.Looseseedscanalsobeplacedusing
the Mick applicator, the clinician should identify a potential
deﬁcit not encountered by the preplanning team. When all
needles are inserted, a cystoscopy is performed to identify4 Advances in Urology
Table 1: LDR brachytherapy: clinical results for patients with low-risk prostate cancer.
Author Number of
patients
PSA relapse
deﬁnition
Median
followup
Years after
diagnosis
% of biochimical
free reccurence
Ellis et al. [21] 239 ASTRO 47 MONTHS 7 96
Zelefsky et al. [22] 319 ASTRO 63 MONTHS 5 96
Zelefsky et al. [23] 1444 ASTRO 63 MONTHS 8 82
Block et al. [24] 118 ASTRO 49 MONTHS 5 94.7
Khaksar et al. [25] 146 ASTRO 45 MONTHS 5 96
Guedea et al. [26] 241 ASTRO 30 MONTHS 3 93
Stock et al. [14] 589 ASTRO 4.2 YEARS 10 94
Prada et al. [27] 275 ASTRO 31 MONTHS 5 96
Potters et al. [28] 481 ASTRO-
Kattan 82 MONTHS 12 89
Sharkey et al. [29] 1707 ASTRO — 12 89
Joseph et al. [30] 667 ASTRO 31 MONTHS 8 84.3
Critz and Levinson [31] 1469 >0.2ng/mL 6 YEARS 10 93
Bladou et al. [32] 177 NOT
DEFINED 29 MONTHS 3 98
Battermann et al. [33] 114 ASTRO 48 MONTHS 5 89
D’Amico et al. [34] 196 ASTRO 3.9 YEARS 5 95
Sylvester et al. [35] 73 2 PSA rises 63 MONTHS 10 89
Kwok et al. [36] 41 ASTRO 7 YEARS 5 85
Grimm et al. [37] 125 2 PSA RISES 81 MONTHS 10 87
Wallner et al. [38] 126 >0.5ng/mL 2.9 YEARS 3 89–91
Martin et al. [39] 273 Houston 5 YEARS 12 90
Merrick et al. [40] 120 ASTRO 31 MONTHS 5 97
whether any needle was placed in the urethra or bladder.
If so, the preloaded strand is removed and reloaded in the
needle for repeated insertion. In their early implantations
the Seattle group used uniform placing of seeds throughout
the prostate. Later, peripheral deposition was used to avoid
high doses to the central part of the gland. In addition,
the initial ultrasound probes did not allow for a biplanar
view, which meant that when the technique originated, only
the transverse image was available, creating the need to rely
upon the preplan and identiﬁcation of a ﬁxed base point
from which to implant all sources. The introduction of the
biplanar probe improved identiﬁcation of the apex and base,
resulting in improved coverage of the ends of the gland [20].
4. ClinicalResults LDR
4.1. Patients with Low-Risk Prostate Cancer. Patients with
low-risk prostate cancer are particularly well suited for low-
dose rate brachytherapy. Although various brachytherapy
regimens, including implant alone, implant plus hormonal
therapy, combined implant, and external-beam radiotherapy
(EBRT), have been used for patients with low-risk cancers,
it has been the consensus of most brachytherapists, as well
as the American Brachytherapy Society, that low-dose rate
brachytherapy alone is the optimal regimen to maximize
cancer control while minimizing morbidity (Table 1). Of the
7 series listed in the table with 10 years of followup, the rate
of durable biochemical control ranges from 87% to 94%.
4.2. Patients with Intermediate-Risk Prostate Cancer. For
patients with intermediate-risk prostate cancer, generally
those with a Gleason score of 7, a PSA value 10, or a palpable
stage T2b tumor, many practitioners have added either hor-
monal therapy or EBRT to confer a high cure rate. At Mount
Sinai, the following treatment algorithm has evolved. The
preferred treatment currently for intermediate-risk prostate
cancer is the combination of neoadjuvant antiandrogen
therapy for a duration of 3 months, followed by a prostate
seed implant to a full dose. This regimen has been shown to
improve outcomes compared with those with brachytherapy
alone. An alternative option is to combine a partial-dose
brachytherapy implant with supplemental EBRT to 45Gy.
Generally, at approximately 7 or more years, the reported
biochemical control rate ranges from approximately 70% toAdvances in Urology 5
Table 2: LDR brachytherapy: clinical results for patients with intermediate-risk prostate cancer.
Author Number of
patients
PSA relapse
Deﬁnition
Median
followup
Years after
diagnosis
% of biochimical
free reccurence
Ellis et al. [21] 239 ASTRO 47 MONTHS 7 87
Zelefsky et al. [22] 47 ASTRO 63 MONTHS 5 89
Zelefsky et al. [23] 960 ASTRO 63 MONTHS 8 70
Khaksar et al. [25] 111 ASTRO 45 MONTHS 5 89
Guedea et al. [26] 119 ASTRO 30 MONTHS 3 88
Stock et al. [14] 318 ASTRO 4.2 YEARS 10 89.5
Potters et al. [28] 554 ASTRO 96 MONTHS 12 78
Sharkey et al. [29] 1707 ASTRO — 12 89
Joseph et al. [30] 667 ASTRO 31 MONTHS 8 73.9
Critz and Levinson [31] 1469 >0.2ng/mL 6 YEARS 10 80
Battermann et al. [33] 114 ASTRO 48 MONTHS 5 75
Sylvester et al. [35] 92 2 PSA rises 63 MONTHS 10 77
Koutrouvelis et al. [41] 68 ASTRO 4 YEARS 5 95
Kwok et al. [36] 33 ASTRO 7 YEARS 5 63
Merrick et al. [40] 273 ASTRO 4.7 YEARS 8 94.8
95% (Table 2). There is certainly also heterogeneity in this
group of patients based upon the deﬁnitions of intermediate
risk used as well as the volume of cancer as determined by
a pretreatment biopsy. With longer followup and improved
staging (such as using percent of biopsy involved with the
tumor), a brachytherapist should be able to further identify
patients with more advanced intermediate-risk features and
determine more precisely which patients would beneﬁt from
the addition of EBRT to the prostate only or to the pelvis
with or without concurrent adjuvant hormone therapy. This
understanding has the potential to bring all treated series to
an 80%–90% freedom from biochemical failure rate at and
beyond 5 years minimum followup.
4.3. Patients with High-Risk Prostate Cancer. From the early
inception of treating prostate cancer with brachytherapy, it
became known that patients with high-risk disease faired
poorly when treated with a seed implant alone [42, 43]. This
knowledge led to the practice of combining brachytherapy
with EBRT to treat these patients. This approach has
resulted in excellent disease control rates (Table 3). At
Mount Sinai, using an approach that involves 9 months
of hormonal therapy, 103-Pa brachytherapy and external-
beam irradiation, the 7-year biochemical control rate was
83% for 360 patients with high-risk prostate cancer [43].
Dattoli et al. [44] reported on 243 patients with high-risk
disease treated with combination therapy and showed an
80% biochemical control rate at 13 years. These excellent
rates compare favorably to those with radical prostatectomy,
especially when one focuses on the subset of patients with
high-grade tumors (Gleason score 8–10). At Mount Sinai
patients with a Gleason score of 8–10 had a 77.5% freedom
from PSA failure (FFPF) rate at 7 years [43]. This appears to
be superior to the 10% to 39% rate found alone after radical
prostatectomy [47, 48].
5. Implant TechniquesHDR
5.1. Advantages of HDR Brachytherapy. When compared to
LDR seed brachytherapy HDR brachytherapy has a number
of advantages. Generally the advantages may be considered
in three areas, the practical, physical and biological. The
practical advantages are self-evident in that there are no
free live sources used, no risk of source loss and, since
the implant is a temporary procedure, following discharge
no issues with regard to radioprotection. Furthermore, it
maximises the use of existing facilities. Most radiotherapy
centres possess an HDR iridium afterloading machine for
other purposes, which makes the procedure cost eﬀective.
The physical advantages of temporary HDR brachytherapy
for the prostate relate to the ability to place afterloading
catheters, not only within the prostate capsule but also
in the extraprostatic tissues, bladder base, and seminal
vesicles. As a result, more advanced cases can be treated
successfully with adequate coverage of extracapsular and
seminal vesicle tumour. The procedure in which the clinical
target volume (CTV) is deﬁned after implantation enables
individualisation of dosimetry according to the potential
sites of actual and microscopic tumour. The calculation of
dosimetry deﬁned by the source dwell positions within each
catheter immediately prior to radiation exposure means that
accuratemeasuresofbothtumourdoseanddosetoorgansat
risk can be relied upon. Furthermore the implant procedure
prevents organ motion and therefore there is no need for6 Advances in Urology
Table 3: LDR brachytherapy: clinical results for patients with high-risk prostate cancer treated with combined brachytherapy and androgen
deprivation or external-beam radiation therapy.
Author Number of
patients
PSA relapse
deﬁnition
Median
followup
Years after
diagnosis
% of biochimical
free reccurence
Ellis et al. [21] 239 ASTRO 47 MONTHS 7 72.5
Dattoli et al. [44] 243 >0.2ng/mL 8.5 YEARS 13 81
Merrick et al. [45] 204 >0.4ng/mL 7 YEARS 10 86.6
Zelefsky et al. [22] 192 ASTRO 63 MONTHS 8 48
Khaksar et al. [25] 43 ASTRO 45 MONTHS 5 93
Guedea et al. [26] 30 ASTRO 30 MONTHS 3 81
Stock et al. [14] 360 ASTRO 4.2 YEARS 7 83
Copp et al. [46] 93 ASTRO 54 MONTHS 4 77
Potters et al. [28] 418 ASTRO 82 MONTHS 12 63
Sharkey et al. [29] 1707 ASTRO — 12 88
Joseph et al. [30] 667 ASTRO 31 MONTHS 8 52.6
Critz and Levinson [31] 1469 >0.2ng/mL 6 YEARS 10 61
Battermann et al. [33] 114 ASTRO 48 MONTHS 5 54
Sylvester et al. [35] 77 2 PSA rises 63 MONTHS 10 47
Koutrouvelis et al. [41] 280 ASTRO 4 .5 YEARS 5 81
Kwok et al. [36] 28 ASTRO 7 YEARS 5 24
an additional margin expanding the CTV to the planning
target volume (PTV). The biological advantage of HDR
brachytherapy relates to the ability to deliver intermittent
highdoseperfractionradiotherapysafelyandconformallyto
thedeﬁnedPTV.Thereisnowextensiveliteraturesupporting
the concept that the radiobiological response of prostate
cancer cells is predominantly described by a survival curve
with a low α/β ratio. The actual ﬁgure remains a matter
of some debate but there is general consensus, it is well
below ﬁve and possibly as low as two or three with the
extreme estimates as low as 1.5 [49]. The implication of
this is that high dose per fraction delivery of radiotherapy
will be biologically more eﬃcient than either conventional
external-beam radiotherapy delivered in 2-3Gy fractions
or LDR seed brachytherapy. Using a simple biologically
equivalent dose (BED) formula without correction for half-
life of repair, the dose increments obtained using HDR boost
schedules after 45Gy in 25 fractions with a boost of 16Gy
in two fractions are of the order of 125% compared with an
external-beam dose of 74Gy in conventional fractionation.
WhenconsideringHDRmonotherapy,thisincrementisover
150% using standard schedules of 36Gy in four fractions. It
is widely accepted that there is a dose response for prostate
cancer, particularly bulky more advanced disease, and it
can be seen therefore that HDR brachytherapy is the most
eﬃcient means of obtaining dose escalation in terms of
biological dose.
5.2. Indications for HDR Brachytherapy. HDR brachytherapy
is delivered in one of two situations, either as a boost
following an intermediate dose of external-beam radiother-
apy, typically 45Gy, or as monotherapy delivering the total
radiation treatment with HDR brachytherapy. Monotherapy
schedules vary from two fractions to nine fractions, the
majority of groups use two to four fractions with a total
doseof26–36Gy.TheGECESTROgroup[50]haspublished
guidelines for patient selection for HDR brachytherapy.
These include patients with any PSA level provided that
there is no demonstrable metastasis, any Gleason score, and
stages T1b to T3b. Exclusion criteria include a volume of
more than 60mL, inﬁltration of the bladder neck, signiﬁcant
urinaryobstructivesymptomsorpubicarchinterferenceand
patients for whom lithotomy or anaesthesia is not possible.
5.3. Procedure. The procedure for HDR brachytherapy
is similar to that for LDR seed brachytherapy using
the transperineal transrectal ultrasound guided approach.
Patients require a spinal or general anaesthetic for the
procedure. HDR afterloading catheters are evenly spaced
within the CTV. Catheter ﬁxation is achieved using a
template ﬁxed to the perineum. Commercially available
programmeswillnowintegrateultrasoundimagestoprovide
a 3D reconstruction of the CTV for planning, whilst the
patient is in the operating room. Alternatively postoperative
CT scans taken after recovery from the procedure enable
more detailed planning prior to treatment exposure. Veriﬁ-
cation using catheter measurements, ﬂuoroscopy, and repeat
scanning before each fraction is essential as postimplant
prostatic oedema and retropubic oedema can alter the
relation between the prostate gland, organs at risk, and the
implanted catheters. Schedules vary but it is possible to
deliver two or three fractions over 36 hours with a single
implant procedure.Advances in Urology 7
Table 4: HDR brachytherapy: percentages biochemical free relapse after combined with external-beam radiation therapy according to risk
group for prostate cancer patients.
Author Number of
patients
% of biochemical free reccurence according to risk group
Years after diagnosis
Low risk Intermediate risk High risk
Astr¨ om et al. [51] 214 100 100 86 4
Flynn et al. [52] 674 97 92 79 5
Galalae et al. [53] 611 96 88 69 5
Galalae et al. [54] 324 —8 5 8 1 5
Guix et al. [55] 445 —9 5 9 4 5
Izard et al. [56] 165 100 95 67 5
Martinez et al. [57] 207 —8 5 7 5 5
Phan et al. [58] 309 100 100 97 5
Yamada et al. [59] 105 100 98 92 5
Demanes et al. [60] 209 93 82 62 10
Ghilezan et al. [61] 1577 —8 8 7 4 10
Hasan et al. [62] 886 93 92 71 10
5.4. Dosimetry. Dosimetry is based on deﬁned dwell time
positions within each catheter. Modern commercial software
programmes allow inﬁnite manipulation and optimisation
of dose using 2.5 or 5mm dwell positions. Dose constraints
for the organs at risk, in particular the rectum, urethra
and bladder can be deﬁned. For example, in Mount Vernon
Cancer Centre United Kindgom for a prescription dose of
8.5Gy the D3
2cmfor the rectum is deﬁned at less than 6.7Gy,
and the V8.5Gy is zero. The urethral D 10% is constrained at
less than 10Gy, the D 30% at less than 9.8Gy and the V10Gy
to zero. HDR afterloading treatment delivery is simple and
well tolerated by the patient. Removal of the implant is
similarly achieved without diﬃculty and with no need for
further anaesthesia.
6. ClinicalResults HDR
6.1. Combined Brachytherapy and External-Beam Radia-
tion Therapy. The greatest clinical experience with HDR
brachytherapy for prostate cancer involves its combination
with external-beam RT. In this context, external-beam RT
is used to treat the prostate and the pelvic tissues (e.g.,
seminalvesicles),inwhichtheremaybemicroscopicdeposits
of cancer. The standard external-beam RT dose varies
somewhatfromonemedicalinstitutiontoanother,butinthe
studies included in the current paper, generally 3600cGy to
5000cGy was delivered in 20 to 28 daily treatment sessions
[51–62]. HDR prostate brachytherapy was used in these
studies to deliver an additional 1200cGy to 3000cGy to the
prostate [51–62]. HDR brachytherapy may be performed
before external-beam RT, after its completion, or in the
midst of this component of RT. In this setting, HDR
brachytherapy is used to deliver a high dose of radiation
to the target to improve tumor control without increasing
the risk of injury to the surrounding healthy organs. The
medical literature reviewed in the current paper collectively
included more than 5000 patients who were treated with
the combination of HDR brachytherapy and external-beam
RT. Most reports describe clinical outcome using freedom
from biochemical relapse as a reporting end point (Table 4).
As discussed by Demanes et al. [60] these results are
comparable to, or better than, results reported with external-
beam RT alone [69, 70] with permanent interstitial LDR
brachytherapy alone [35, 70] or with the combination of
external-beam RT and LDR brachytherapy [70]. Radiation
doses used in HDR brachytherapy were initially selected
to some extent on a presumption of eﬃcacy and with
safety in mind. However, Galalae et al. increased the HDR
brachytherapy dose in a stepwise manner in an attempt to
identify an optimal dose [54]. Their research demonstrated
that a dose of 1650cGy or greater delivered in 2 sessions,
which is now considered a high dose, led to improved
results regarding freedom from biochemical relapse. The
combination of HDR brachytherapy and external-beam
RT appears to be well tolerated by most patients. Severe
gastrointestinaladverseeventstypicallyoccurinlessthan1%
ofpatients[52,55–60]andmoderategastrointestinaladverse
events are experienced by approximately 5% of patients
[52, 55, 56, 58–60]. Similarly, severe genitourinary adverse
events, mainly consisting of urethral stricture responsive
to dilatation, are not apt to occur [55–60, 71], whereas
mild to moderate genitourinary adverse events occur in
approximately 10% of patients [55, 56, 58–60]. Duchesne
et al. [72] noted that adverse events resolve in two-thirds
of aﬀected patients after combination therapy, so chronic
sequelae are decidedly uncommon. Urinary incontinence
was noted in less than 4% of patients, mainly occurring only
inthesettingofpreviousorsubsequentTURP(transurethral
prostatectomy). Demanes et al. [60] reported that erectile
function is preserved in approximately two-thirds of patients
with prostate cancer after combination therapy.
6.2. HDR Brachytherapy Alone. High-dose-rate brachyther-
apy is also used as the sole method of administering RT for
prostate cancer without the addition of external-beam RT.
This treatment strategy was developed largely independently
at several medical centers. Thus, the number of implantation
sessions, the number of treatments, and the prescribed dose8 Advances in Urology
Table 5: Clinical results after HDR brachytherapy alone for patients with low- and intermediate-risk prostate cancer.
Author Number of
patients
Free biochemical
reccurence (%)
Cause speciﬁc
survival (%)
Local control (%) Years after diagnosis
Demanes et al. [63] 298 94 100 100 5
Ghilezan et al. [64] 95 98 100 100 5
Grills et al. [65] 65 98 — —3
Mark et al. [66] 206 89 — —5
Rogers et al. [67] 328 96 low risk
89 intermediate risk 100 —3
Yoshioka et al. [68] 111 100 low risk
89 intermediate risk — 100 3
have varied somewhat. In performing HDR brachytherapy
alone, 1 or 2 implantation sessions have been used to
deliver 4 or 6 doses of 600cGy to 950cGy each, for a total
dose of 3800cGy to 5400cGy [63–68, 73]. This approach
has provided excellent intermediate-term results regarding
freedom from biochemical relapse for certain groups of
patients with prostate cancer (Table 5)[ 63–68, 73].
T h e s eo u t c o m e sa p p e a rt oc o m p a r ef a v o r a b l yw i t h
results of permanent LDR brachytherapy [64, 65, 74]a n d
with results of the combination of HDR brachytherapy
and external-beam RT [75, 76]. Nevertheless, the reported
patient followup duration after HDR brachytherapy alone
has been shorter than that available for patients treated
with combined HDR brachytherapy and external-beam RT.
Consequently, the favorable results for HDR brachytherapy
alone should be considered somewhat tentatively. High-
dose-ratebrachytherapyistypicallywelltoleratedbypatients
with prostate cancer, and the rate and severity of adverse
events associated with this treatment compare favorably with
permanent interstitial LDR brachytherapy [65]. However,
approximately one-half to two-thirds of patients treated
with HDR brachytherapy experience acute dysuria, urinary
frequency and urgency, or urinary retention [65, 68, 73].
The rate of intermittent self-catheterization for urinary
retention is less than 5% [63, 65, 67, 68, 73]. Although
diarrhea, proctalgia, and hematochezia can occur, these
adverse eﬀects are infrequently encountered [63, 65–68, 73].
Acute adverse events are usually mild and resolve spon-
taneously, but short-term medicinal therapy may improve
genitourinary function and patient comfort. Most patients
d on o th a v el a t ee ﬀects from HDR brachytherapy, but
dysuria, urinary frequency and urgency, urinary retention,
hematuria, diarrhea, proctalgia, and hematochezia can occur
[63, 65, 66, 68]. These eﬀects tend to be mild and resolve
spontaneously [65] but patient recovery may require several
months. Urinary stress incontinence and urethral stricture
are observed in less than 5% of patients treated with HDR
brachytherapy alone [63, 65, 66, 68] and erectile dysfunction
is estimated to occur in 16% of patients [65].
7. Conclusions
Prostate brachytherapy is an excellent treatment modality
for localized prostate cancer. The major side eﬀects are
temporary urinary symptoms. In the future, we will most
probablybeabletobetterinformpatientsabouttheirspeciﬁc
r i s k so fs i d ee ﬀects, thereby decreasing substantially the
inﬂuence of any given physician’s therapeutic bias in the face
of several reportedly equivalent therapies.
Recent technological advances in HDR brachytherapy
have increased the appeal and application of this approach
forpatientswithlocalizedprostatecancer.Currenttreatment
methods allow administration of a high dose of radiation
that tightly conforms to the targeted volume while minimiz-
ing radiation exposure to adjacent healthy organs. Because
optimized dose distributions are generated before treatment,
high-quality treatment can be assured. To date, patient care
data suggest that an impressive therapeutic outcome, with
a low rate of adverse events, can be achieved with HDR
brachytherapy.
However, several issues regarding HDR brachytherapy
remain to be adequately addressed. The ideal radiation
dose and number of fractions are not yet known because
direct comparisons between various treatment regimens
are lacking. Ongoing clinical studies are investigating the
feasibility of performing a single implantation, during which
only 1 treatment is administered in conjunction with a short
course of external-beam RT. This approach would reduce
health care costs and medical personnel workload, and it
would likely improve patient comfort and convenience.
Randomized clinical trials are needed to directly com-
pare HDR brachytherapy with other forms of treatment
for prostate cancer, particularly LDR brachytherapy and
external-beam RT. Randomized clinical trials are also needed
to determine whether androgen suppression should be inte-
grated into the overall treatment strategy for some patients.
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